We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
Revvity The Alphalisa® Surefire® Ultra™ Human Phospho-Pkr


Revvity Protein kinase R (PKR) is a kinase encoded by the EIF2AK2 gene and is involved in central cellular processes such as mRNA translation, transcriptional control, regulation of apoptosis, and proliferation. PKR plays a key role in the innate immunity pathway and is a mediator of the antiviral effects exerted by interferons. PKR also regulates eIF2α through phosphorylation. Dysregulation of PKR has been implicated in cancer, neurodegenerative disease, inflammation, and metabolic disorders. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)
Revvity The AlphaLISA SureFire Ultra Human Phospho-PKR (Thr451) assay is a sandwich immunoassay for the quantitative detection of phospho-PKR (Thr451) in cellular lysates, using Alpha Technology. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)
Formats:
The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.AlphaLISA SureFire Ultra kits are compatible with:
Cell and tissue lysatesAntibody modulatorsBiotherapeutic antibodiesAlpha SureFire kits can be used for:
Cellular kinase assaysReceptor activation studiesScreening| SKU | REVPFZ-ALSU-PPKR-B50K |
|---|---|
| Supplier Part Number | ALSU-PPKR-B50K |
| UM | PK |
| UNSPSC | 41105332 |
| Manufacturer | Revvity |
| CountryOfOrigin | Australia |
| ProductLine | REVPFZ |
| Qty | 10000 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 5 |
| Hazardous | N |
| Energy Star | No |
| Green | No |
| Controlled | N |

